Overview

Study to Demonstrate Cognitive Enhancing Effects of BF2.649

Status:
Completed
Trial end date:
2011-10-01
Target enrollment:
Participant gender:
Summary
To evaluate the cognitive enhancing effect of BF2.649 and to evaluate the effect of BF2.649 on symptom severity in persons with schizophrenia or schizoaffective disorder.
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
Bioprojet
Stanley Medical Research Institute